Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Drohnen, Robotik, E-Autos: Diese Hightech-Aktie könnte jetzt zünden
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
237 Leser
Artikel bewerten:
(1)

Covation Biomaterials Highlights Milestones for CovationBio bioPTMEG at K-Show 2025

DUSSELDORF, Germany, Oct. 8, 2025 /PRNewswire/ -- Covation Biomaterials LLC ("CovationBio® "), a biomaterials company with advanced technology in the bio-based materials industry, is excited to share project milestones and updates for their newest innovation, CovationBio® bioPTMEG at K 2025, the world's leading trade fair for plastics and rubber.

First announced at ChinaPlas in April 2025, CovationBio® bioPTMEG is an advanced, sustainable polytetramethylene ether glycol (PTMEG), that delivers high performance with a significantly lower production emissions compared with fossil-based incumbents.

"Through continued work with our customers, we are achieving significant milestones against the goal of making bioPTMEG commercially available. Specifically, CovationBio® bioPTMEG, a sustainable PTMEG product utilizing advanced technology, delivering peak performance with the lowest environmental impact. It truly redefines what's possible from biobased materials," said Feifeng You, President of CovationBio.

CovationBio® bioPTMEG is a bio-based alternative to fossil-based PTMEG, helping customers reduce their reliance on non-renewable materials and maintain the durability and resilience expected in high performance applications such as spandex, polyurethanes and thermoplastic elastomers.

A few of the superior sustainability benefits offered include:

  • a substantial reduction of greenhouse gas emissions compared to fossil-based incumbents;
  • a product that is 100% bio-based and obtained from annually renewable resources;
  • the use of feedstock such as corncobs which do not compete with primary food sources;
  • a reduced reliance on non-renewable fossil fuel use.
  • Drop-in performance to allow downstream customers to switch to bio-based raw material without major process change.

As earlier announced at ChinaPlas 2025, the construction of a dedicated manufacturing facility for CovationBio® bioPTMEG which is expected to be mechanically complete toward the end of 2025. It is located in Jiangsu Province, Qidong. Commercial production should begin in the first half of 2026.

Aligned with this year's K Show theme, "The Power of Plastics! Green - Smart - Responsible," our Covation Biomaterials team are ready to share more about how CovationBio® bioPTMEG can integrate into downstream high performance materials such as TPU, PU, COPE, COPA and spandex to advance sustainability strategies with our value chain partners in multiple applications.

Please visit the team in Hall 5, Booth C07-1.

On October 10th 2025, Dr. Mosha Zhao, Global Marketing Director for C4 Platform, and Dr. Dan Slanac, Global Technology Director of CovationBio, will introduce this innovation journey from non-food bio-based feedstock to renewable raw materials: Redefine What's Possible to Reduce Carbon Footprint at the Bioplastics Business Breakfast Days Conference (Congress Centre, Hall 1).

For those interested in learning more, please contact us at bioPTMEG@covationbio.com.

Disclaimer: The statements above are taken from the product's life cycle analysis (LCA) and product performances are based on tests by Covation Biomaterials LLC and TrueNorth Collective LLC.

About CovationBio®
Founded in 2022, in Newark, Delaware, Covation Biomaterials LLC is a biomaterials company with advanced technology in the bio-based materials industry, offering a product portfolio of high-performance, sustainable solutions. The company builds on its rich DuPont legacy of groundbreaking scientific innovation and continues to deliver novel solutions at scale across multiple industries, including apparel, carpeting, cosmetics, food, and packaging. Through the Sorona®, Susterra® and Zemea® product lines, the mission of CovationBio® is to deliver building blocks that will enable customers to provide bio-based products accessible to everyone. Covation, CovationBio®, Sorona, Susterra, and Zemea are trademarks of Covation Biomaterials LLC or their affiliates. For more information about Covation Biomaterials, please visit CovationBio.com and follow on WeChat, LinkedIn, Instagram, and Facebook

Photo - https://mma.prnewswire.com/media/2782989/image_5012424_40927877.jpg

Cision View original content:https://www.prnewswire.co.uk/news-releases/covation-biomaterials-highlights-milestones-for-covationbio-bioptmeg-at-k-show-2025-302574610.html

© 2025 PR Newswire
Favoritenwechsel
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.